Innovacell Inc is engaged in the development, manufacturing, and sale of regenerative medicine products for the treatment of conditions including fecal and urinary incontinence. Innovacell (TKS: 504A) is based in Tokyo, Japan. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $364 million (Feb 2026). It has raised $193 million.
Last price · $/share
—
Implied valuation
$364.2M
Total raised
$193.4M
Last round
—
No prints on record
No secondary trades in Innovacell (TKS: 504A) shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Innovacell (TKS: 504A) with a free account
·The complete investor list: 26 names
·Watch Innovacell (TKS: 504A): the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Innovacell (TKS: 504A) stock.
